453 related articles for article (PubMed ID: 32922387)
1. HLA-G Neo-Expression on Tumors.
Loustau M; Anna F; Dréan R; Lecomte M; Langlade-Demoyen P; Caumartin J
Front Immunol; 2020; 11():1685. PubMed ID: 32922387
[TBL] [Abstract][Full Text] [Related]
2. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.
Anna F; Bole-Richard E; LeMaoult J; Escande M; Lecomte M; Certoux JM; Souque P; Garnache F; Adotevi O; Langlade-Demoyen P; Loustau M; Caumartin J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737343
[TBL] [Abstract][Full Text] [Related]
3. HLA-G: A New Immune Checkpoint in Cancer?
Krijgsman D; Roelands J; Hendrickx W; Bedognetti D; Kuppen PJK
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630545
[TBL] [Abstract][Full Text] [Related]
4. The immunosuppressive molecule HLA-G and its clinical implications.
González A; Rebmann V; LeMaoult J; Horn PA; Carosella ED; Alegre E
Crit Rev Clin Lab Sci; 2012; 49(3):63-84. PubMed ID: 22537084
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: human leukocyte antigen G (HLA-G).
Curigliano G; Criscitiello C; Gelao L; Goldhirsch A
Clin Cancer Res; 2013 Oct; 19(20):5564-71. PubMed ID: 23897901
[TBL] [Abstract][Full Text] [Related]
6. HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease.
Martín-Villa JM; Vaquero-Yuste C; Molina-Alejandre M; Juarez I; Suárez-Trujillo F; López-Nares A; Palacio-Gruber J; Barrera-Gutiérrez L; Fernández-Cruz E; Rodríguez-Sainz C; Arnaiz-Villena A
Front Immunol; 2022; 13():796054. PubMed ID: 35154112
[TBL] [Abstract][Full Text] [Related]
7. HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies.
Morandi F; Airoldi I
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328349
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies.
Yie SM; Hu Z
Histol Histopathol; 2011 Mar; 26(3):409-20. PubMed ID: 21210353
[TBL] [Abstract][Full Text] [Related]
10. Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.
Zheng G; Jia L; Yang AG
Front Immunol; 2022; 13():791975. PubMed ID: 35185887
[TBL] [Abstract][Full Text] [Related]
11. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
12. HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers.
Li P; Wang N; Zhang Y; Wang C; Du L
Front Immunol; 2021; 12():791535. PubMed ID: 34868081
[TBL] [Abstract][Full Text] [Related]
13. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance.
Loumagne L; Baudhuin J; Favier B; Montespan F; Carosella ED; Rouas-Freiss N
Int J Cancer; 2014 Nov; 135(9):2107-17. PubMed ID: 24623585
[TBL] [Abstract][Full Text] [Related]
14. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
16. The dual role of HLA-G in cancer.
Rouas-Freiss N; Moreau P; LeMaoult J; Carosella ED
J Immunol Res; 2014; 2014():359748. PubMed ID: 24800261
[TBL] [Abstract][Full Text] [Related]
17. CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.
Sacchetti B; Botticelli A; Pierelli L; Nuti M; Alimandi M
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999624
[TBL] [Abstract][Full Text] [Related]
18. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
Carosella ED; Gregori S; Tronik-Le Roux D
Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.
Lin A; Yan WH
Front Immunol; 2018; 9():2164. PubMed ID: 30319626
[TBL] [Abstract][Full Text] [Related]
20. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
